IRIDEX Corporation (IRIX)
NASDAQ: IRIX · Real-Time Price · USD
1.030
0.00 (0.00%)
Apr 14, 2026, 4:00 PM EDT - Market closed
IRIDEX Revenue
In the fiscal year ending January 3, 2026, IRIDEX had annual revenue of $52.68M with 8.23% growth. IRIDEX had revenue of $14.72M in the quarter ending January 3, 2026, with 15.97% growth.
Revenue (ttm)
$52.68M
Revenue Growth
+8.23%
P/S Ratio
0.34
Revenue / Employee
$566,398
Employees
93
Market Cap
17.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jan 3, 2026 | 52.68M | 4.01M | 8.23% |
| Dec 28, 2024 | 48.67M | -3.20M | -6.17% |
| Dec 30, 2023 | 51.87M | -5.10M | -8.96% |
| Dec 31, 2022 | 56.97M | 3.07M | 5.69% |
| Jan 1, 2022 | 53.90M | 17.56M | 48.30% |
| Jan 2, 2021 | 36.35M | -7.10M | -16.34% |
| Dec 28, 2019 | 43.45M | 847.00K | 1.99% |
| Dec 29, 2018 | 42.60M | 1.01M | 2.42% |
| Dec 30, 2017 | 41.59M | -4.57M | -9.89% |
| Dec 31, 2016 | 46.16M | 4.40M | 10.54% |
| Jan 2, 2016 | 41.76M | -1.06M | -2.47% |
| Jan 3, 2015 | 42.81M | 4.54M | 11.86% |
| Dec 28, 2013 | 38.27M | 4.41M | 13.04% |
| Dec 29, 2012 | 33.86M | 700.00K | 2.11% |
| Dec 31, 2011 | 33.16M | 851.00K | 2.63% |
| Jan 1, 2011 | 32.31M | 1.28M | 4.11% |
| Jan 2, 2010 | 31.03M | - | - |
| Jan 3, 2009 | - | - | - |
| Dec 29, 2007 | - | - | - |
| Dec 30, 2006 | 35.90M | -1.13M | -3.04% |
| Dec 31, 2005 | 37.03M | 4.22M | 12.86% |
| Jan 1, 2005 | 32.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TELA Bio | 80.28M |
| Trinity Biotech | 48.57M |
| Myomo | 40.93M |
| Lifeward | 22.03M |
| Vivos Therapeutics | 17.32M |
| Pulsenmore | 12.55M |
| IceCure Medical | 3.38M |
| VolitionRx | 1.73M |
IRIX News
- 7 days ago - Iridex Announces New Partnership with EyeProGPO to Expand Member Access to Retina Laser Technology - GlobeNewsWire
- 19 days ago - Iridex Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Iridex to Report Fourth Quarter and Full Year 2025 Financial Results on March 26, 2026 - GlobeNewsWire
- 2 months ago - Iridex Announces Plans to Relocate Headquarters - GlobeNewsWire
- 3 months ago - Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025 - GlobeNewsWire
- 4 months ago - Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management - GlobeNewsWire
- 4 months ago - Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment - GlobeNewsWire
- 4 months ago - Iridex to Present at the Sidoti Year-End Virtual Investor Conference - GlobeNewsWire